Abstract 1953
Background
Targeted therapy of advanced non-small-cell lung cancer (NSCLC) has changed the outcome of patients with specific gene alterations. In particular, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors have improved the outcome of patients with EGFR-mutated lung adenocarcinoma (ADC). We analyzed the frequency of other potentially targetable driver alterations in a series of advanced EGFR-wild type (wt) NSCLC patients.
Methods
461 advanced EGFR-wt NSCLC patients enrolled from Area Vasta Romagna between January 2013 to December 2014 were included in the study. KRAS, BRAF, ERBB2, PIK3CA, NRAS, ALK, MAP2K1, RET and DDR2 mutations were analyzed by Myriapod®Lung Status kit (Diatech Pharmacogenetics) on Maldi-TOF Mass Spectrometry (MassARRAY® AGENA BIOSCIENCE). ERBB4 was evaluated by direct sequencing and EML4-ALK and ROS1 rearrangements were assessed by immunohistochemistry or fluorescence in situ hybridization.
Results
217 (47%) patients showed at least one alteration. In particular, 71%, 6.5%, 2.7%, 1.8%, 1.4% and 1.4% patients had mutations in KRAS, BRAF, PIK3CA, NRAS, ERBB2 and MAP2K1 genes, respectively. Only one (0.5%) patient showed a mutation in ERBB4 gene. EML4-ALK and ROS1 rearrangements were observed in 10.6% and 4.1% patients, respectively. The clinical characteristics of mutated patients are reported in Table 1. Overlapping mutations were observed in 5 (2.3%) KRAS-mutated patients: one (20%) was mutated in PIK3CA, 3 (60%) showed an EML4-ALK translocation and one (20%) had a ROS1 rearrangement. One (0.5%) patient showed both BRAF and PIK3CA alterations. Correlation analyses between the different mutations and patient outcome are ongoing. Table.
Gene | No. of mutated patients | Age | Gender | Smoking Habits | ||||
---|---|---|---|---|---|---|---|---|
ConclusionsDriver mutations were detected in about 50% of EGFR-wt lung ADC patients. Such alterations could represent potential targets for therapy and could be evaluated in routine multiplexed testing to obtain a wider tumor molecular characterization. Clinical trial identificationNot applicable Legal entity responsible for the studyIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)-IRCCS FundingN/A DisclosureAll authors have declared no conflicts of interest. Resources from the same session2354 - The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institutionPresenter: Seung Tae Kim Session: Poster Display Resources: Abstract 2594 - Neuroendocrine carcinomas of the colorectal origin - Polish experiencePresenter: Agnieszka Kolasińska-Ćwikła Session: Poster Display Resources: Abstract 2539 - Neuroendocrine neoplasms of the appendix including goblet cell carcinoidsPresenter: Agnieszka Kolasinska-Cwikla Session: Poster Display Resources: Abstract 1245 - Prognostic validity of AJCC staging system in neuroendocrine tumors of the appendixPresenter: Amir Mehrvarz Sarshekeh Session: Poster Display Resources: Abstract 3902 - Enhancer of zest homolog 2 (EZH2) expression in well and moderately differentiated pancreatic neuroendocrine tumor (pNET)Presenter: Riccardo Marconcini Session: Poster Display Resources: Abstract 3882 - Differential clinical and pathological characteristics of hereditary neuroendocrine pancreatic tumours (NEPT)Presenter: Gema Marín Zafra Session: Poster Display Resources: Abstract 2296 - Natural course of thyroid cancer nodules compared with benign thyroid nodulesPresenter: Kyung-Jin Yun Session: Poster Display Resources: Abstract 4083 - Reassessment of proliferative activity at disease progression in neuroendocrine neoplasmsPresenter: Noemi Cicchese Session: Poster Display Resources: Abstract 3866 - 18F-FDG-PET to predict disease progression in advanced digestive neuroendocrine neoplasmsPresenter: Maria Rinzivillo Session: Poster Display Resources: Abstract 3651 - UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The “real-world” OBLIQUE studyPresenter: John Ramage Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|